Recruiting
Phase 2

Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Sponsor:

Sabine Mueller, MD, PhD

Code:

NCT05465174

Conditions

Craniopharyngioma, Child

Craniopharyngioma

Recurrent Craniopharyngioma

Eligibility Criteria

Sex: All

Age: 1 - 39

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Tovorafenib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Sabine Mueller, MD, PhD on 2025-03-25.